Biologic facts
BrandSkyrizi (Risankizumab)
No biosimilar to Skyrizi is licensed. The 12-year reference exclusivity date of 04/2031 is an estimate from first approval; the Purple Book does not list patents, which can protect a biologic longer.
Skyrizi was first approved by the FDA in 2019; the application holder is Abbvie Inc.
The latest NADAC for SKYRIZI 150 MG/ML PEN is $22,795.09 per mL (as of 10/28/2026).
Holder Abbvie Inc.Approved 2019
01Exclusivity
When biosimilar competition can legally begin. The Purple Book lists reference exclusivity but not patents, which can protect a biologic longer.
- Patents
- Not listed in the Purple Book Purple Book
- Reference exclusivity
- 04/203112-year estimate from first approval Purple Book
02Competition
- Biosimilars
- No biosimilar approved Purple Book
Every makerEach licensed product and biosimilar maker.
PrescribersWho prescribes it, from Medicare data.
Spend and safetyMedicare Part B spend and safety reports.
Available in the full Skyrizi profile.See what is included
03Supply and price
- FDA drug shortage
- ClearNot on the current shortage list FDA shortages
- NADAC
- $22,795.09 per mLSKYRIZI 150 MG/ML PEN, as of 10/28/2026 CMS NADAC
04Product
- Application holder
- Abbvie Inc. Purple Book
- First approved
- 2019 Purple Book
Sources: FDA Orange Book, FDA Purple Book, FDA drug shortages, FDA enforcement reports and CMS NADAC, read through QOPE. Not medical or legal advice.